~~We~~ Claim~~s~~

1. Use of methazolamide in the manufacture of a medicament for ~~A method of~~ effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent~~, said method comprising the step of further administering an effective amount of methazolamide to said patient~~.

~~2. A method of effecting weight loss in a patient comprising:~~

~~(i) commencing treatment with an anti-diabetic agent;~~

~~(ii) continuing treatment with the anti-diabetic agent; and~~

~~(iii) subsequently commencing additional treatment with effective amount of methazolamide.~~

~~3~~2. The use ~~A method~~ according to claim 1 ~~or 2~~ wherein the methazolamide ~~treatment~~ is formulated for administration~~commenced~~ once the patient's blood glucose levels are stabilised by the anti-diabetic agent.

~~4~~3. The use~~method~~ according to ~~any one of~~ claim~~s~~ 1 or claim 2~~-3~~ wherein the medicament is for administration of methazolamide at a dosage rate of ~~is administered in an amount~~ less than 100 mg per day.

4. The use according to claim 3 wherein the medicament is for administration of methazolamide at a dosage rate of about 90 mg, 80 mg or 75 mg per day.

5. The use according to claim 4 wherein the medicament is for administration at a dosage rate of about 80 mg per day by administration of a dosage of about 40 mg twice daily.

~~5~~6. The use~~method~~ according to any one of claims 1-~~4~~ 5 wherein the anti-diabetic agent is metformin.

~~6~~7. The use~~method~~ according to any one of claims 1-~~5~~ 6 wherein the methazolamide and

anti-diabetic agents are formulated for oral ~~administered~~ administration~~orally~~, either simultaneously or separately.

~~7~~8. The use~~method~~ according to any one of claims 1-~~6~~ 7 wherein the patient has a body mass index (BMI) of at least 25.

~~8~~9. The use~~method~~ according to any one of claims 1-~~7~~ 8 wherein the patient has a waist measurement of greater than 94 cm (adult men) or greater than 80 cm (adult women).

10. Use of methazolamide in the manufacture of a composition for effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent, wherein said composition comprises methazolamide, together with one or more pharmaceutically acceptable additives, and an anti-diabetic agent.

11. Use of methazolamide in the manufacture of a combination medicament for effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent, wherein said combination medicament comprises methazolamide and an anti-diabetic agent.

~~9. Methazolamide for use in effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent.~~

~~10. A composition for effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent, said composition comprising methazolamide, together with one or more pharmaceutically acceptable additives.~~

~~11. Use of methazolamide in the manufacture of a medicament for effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent.~~

~~12. A combination for use in effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent, said combination comprising methazolamide and an anti-diabetic agent.~~

12. A composition, comprising:
methazolamide in an amount of from about 80 mg to <100 mg;
metformin, and
one or more pharmaceutically acceptable additives.

13. A combination, comprising:
methazolamide in an amount of from about 80 mg to <100 mg, and
metformin.

14. The composition of claim 12 or the combination of claim 13, wherein the amount of methazolamide is 80 mg.

15. The composition of claim 12 or 14 or the combination of claim 13 or 14 in single daily dose form.

16. The composition of claim 12 or 14, or the combination of claim 13 or 14, in divided daily dose form.

17. The composition of claim 12 or 14-16, or the combination of claims 13-16, wherein the amount of metformin is 500 mg – 4,500 mg or 100 – 2000 mg or 50 – 1000 mg.

18. The composition of any one of claims 12 or 14-17, or the combination of any one of claims 13-17, wherein the amount of metformin is selected from 1,250 mg and 1,545 mg.

19. The composition of any one of claims 12 or 14-17, or the combination of any one of claims 13-17, wherein the amount of metformin is selected from 500, 750, 850 and 1,000 mg.

20. The composition of any one of claims 12 or 14-19, or the combination of any one of claims 13-19, wherein the metformin is a pharmaceutically acceptable salt of metformin.

21. The composition of any one of claims 12 or 14-20, or the combination of any one of claims 13-20, wherein the metformin is metformin hydrochloride.

22. The composition of any one of claims 12 or 14-21, wherein the methazolamide and metformin are formulated together as an intimate composition.